M. F. Orth

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma

This study shows EIF4EBP1 is upregulated by MYCN and linked to poor prognosis in neuroblastoma, with high expression associated with reduced survival and unfavorable histology.

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

Systems biology analysis identifies TCF7L1 as a key regulator of metastasis in Ewing sarcoma

Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

Focal adhesion kinase confers pro-migratory and anti apoptotic properties and is a potential therapeutic target in Ewing sarcoma

This study shows FAK promotes migration and prevents apoptosis in Ewing sarcoma via Y397 phosphorylation, suggesting FAK inhibitors could target metastasis.

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

Expression patterns of PD-L1 and PD-1 provide rationales for immune checkpoint inhibition in soft tissue sarcomas

This study examines PD-L1 and PD-1 expression in soft tissue sarcomas and finds associations with TILs and poor clinical outcomes, supporting immune checkpoint inhibition in PD-L1-positive cases.

Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

Targeting the CALCB/RAMP1-axis inhibits growth of Ewing sarcoma

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma

This study identifies AMPD2 as a prognostic biomarker for undifferentiated pleomorphic sarcoma using transcriptome analysis, immunohistochemistry, and functional assays.

Systematic identification of cancer-specific MHC-binding peptides with RAVEN

The paper introduces RAVEN, a software tool that identifies cancer-specific genes encoding MHC-affine peptides from gene expression data, validated across 50 cancer types.

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets

This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.